SHPH heads into its May 21 earnings call as a company mid-transformation — abandoning its pharmaceutical identity for Dogecoin mining, while short sellers who crowded the trade are rushing for the exits.
The most striking data point this week is the speed of short covering. Short interest collapsed 80% over five trading days, falling from a peak near 1 million shares on May 4 to just 118,000 shares on May 14 — leaving SI at 7.4% of free float. That's still elevated for a micro-cap, but the direction of travel is emphatic. The covering followed a dramatic build: SI more than doubled month-on-month from roughly 64,000 shares in early April. Shorts piled in as news of the United Dogecoin merger broke, then retreated sharply before the Q1 earnings print scheduled for next Wednesday.
The borrow market tells the same story, but with more texture. Cost to borrow is extremely expensive at 105% annually, and that is actually the low end of the past two weeks — CTB peaked above 190% in early May as shorts competed for limited stock to borrow. It has since come off roughly 40% in a week, consistent with the short covering. Availability is running at 147% of outstanding short interest, meaning there is meaningfully more stock available to borrow than is currently lent out. That loosening reflects returned borrows as shorts close positions, not fresh supply. Availability was near zero when the squeeze pressure was at its worst earlier in May; its current recovery is the borrow market exhaling.
The company itself looks very different from the pharmaceutical play it once was. On May 7, SHPH completed a merger with United Dogecoin and simultaneously announced a purchase order for up to 3,000 ElphaPex Dogecoin and Litecoin mining rigs. A concurrent $3.5 million public offering followed on May 12. Q1 earnings — released May 15 — showed EPS of -$0.43, a vast improvement on the -$7.60 loss per share from a year ago, though meaningful year-on-year comparisons are complicated by the fundamental change in business model. The ORTEX short score has dropped from a peak of 81.9 on May 4 to 59.8 now, tracking the unwinding in real time.
The earnings history adds a relevant backdrop. The last three confirmed events produced outsized moves: +25.7% on the day of the March 31 announcement, +11.8% on an April 1 event, and -19.2% following the November 2025 print. A company in the middle of a crypto pivot, with elevated borrow costs, a recent equity dilution, and a complex 8-K filings trail, carries a wide range of outcomes around a catalyst. The 1-day moves averaged well above 10% in magnitude across those three events.
Close peers CRVS and ATOS both fell sharply over the past week — down 21% and 13% respectively — reinforcing broader micro-cap biotech/specialty weakness that has been the backdrop to SHPH's own 3.4% weekly slide. Against that peer selloff, SHPH's relative resilience could be read as short covering providing support rather than any fundamental buying.
The next data point worth watching is next Wednesday's earnings call — the first full disclosure event since the company formally became a crypto-mining operation, and one that will clarify whether the $3.5 million offering and mining rig purchase order are the beginning of a capitalised buildout or the ceiling of current financial capacity.
See the live data behind this article on ORTEX.
Open SHPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
